initial antibody or its fragment u0430 u043d u0442 u0438 u0433 u0435 u043d u0441 u0432 u044f u0437 u044b u0432 u0430 u044e u0449 u0438 u0439 (options), the u043f u043e u043b u0438 u043d u0443 u043a u043b u0435 u043e u0442 u0438 u0434 (options), the polypeptide (options), cell hostcomposition (variants) and a method of treatment of cns disease or animal organism (options)

• 收藏
• 分享

专利权人:

BIOGEN MA INC.

发明人:

SHA, MI,R. BLAKE, PEPINSKY,ZHAOHUI, SHAO,ELLEN A. GARBER, STARK,STEVEN D., MIKLASZ,CHRISTILYN, GRAFF

申请号：

TR201807425

公开号：

TR201807425T4

申请日:

2008.01.09

申请国别(地区):

TR

年份:

2018

代理人:

摘要：

endogenous Sp35 is a negative regulator u0430 u043a u0441 u043e u043d u043e u0432 neuron survival, regeneration, differentiation u043e u043b u0438 u0433 u043e u0434 u0435 u043d u0434 u0440 u0438 u0442 u043e u0432 and u043c u0438 u0435 u043b u0438 u043d u0438 u0437 u0430 u0446 u0438 u0438.molecules that block endogenous Sp35 function such as antibodies to Sp35, can be used as medicines for the treatment of u0434 u0438 u0441 u0444 u0443 u043d u0446 u0438 u0438 neurons and u043e u043b u0438 u0433 u043e u0434 u0435 u043d u0434 u0440 u0438 u0442 u043e u0432.the present invention provides antibodies specific for Sp35, and uses the data as a function of antibody antagonists of endogenous Sp35.the invention further provides u0433 u0438 u0431 u0440 u0438 u0434 u043e u043c u0443 and specific monoclonal antibodies isolated from u0444 u0430 u0433 u043e u0432 u043e u0439 nucleic acid libraries for data an. u0442 u0438 u0442 u0435 u043b u0430, and vectors and host cells.with these antibodies.in addition, the invention provides methods to stimulate the survival u043e u043b u0438 u0433 u043e u0434 u0435 u043d u0434 u0440 u0438 u0442 u043e u0432 and u043c u0438 u0435 u043b u0438 u043d u0438 u0437 u0430 u0446 u0438 u044e and vertebrates.including introduction to the treatment effective amount of antibodies to Sp35 spine.Endojen Sp35 nöronal hayatta kalım, akson rejenerasyonu, oligodendrosit farklılaşması ve miyelinasyona yönelik negatif bir regülatördür. Endojen Sp35 fonksiyonunu engelleyen moleküller, örneğin anti-Sp35 antikorlar nöron ve oligodendrosit disfonksiyonunun tedavisine yönelik terapötikler olarak kullanılabilir. Mevcut buluş Sp35?e spesifik antikorlar ve bu tür antikorların endojen Sp35 fonksiyonunun antagonistleri olarak kullanım yöntemlerini sağlar. Buluş ayrıca spesifik hibridoma ve faj kütüphanesinden derive edilmiş monoklonal antikorlaro, bu antikorları kodlayan nükleik asitleri ve bu antikorları içeren vektörleri ve konak hücreleri sağlar. Buluş ayrıca b

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/